Clinical Trial Update: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of IMC-001 in subjects with relapsed or refractory extranodal NK/T-cell lymphoma, nasal type; the study is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• IMC-001

Snippet

Sponsor: ImmuneOncia Therapeutics Inc. | Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING